MedTrace Logo

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

NCT03275350 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2022-04-27

Study results available
· View outcomes & findings →

Summary

The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.

Conditions

  • Opioid-use Disorder
  • Hiv

Interventions

DRUG

Naltrexone Injectable Suspension

Six monthly injections of extended-release naltrexone

OTHER

Treatment as usual

Standard treatment for opioid use disorder provided at each HIV clinic

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Johns Hopkins University

    collaborator OTHER

  • University of Kentucky

    collaborator OTHER

  • Jackson Health System

    collaborator OTHER

  • Tarzana Treatment Centers

    collaborator OTHER

  • Ruth M. Rothstein CORE Center

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-05
Primary Completion
2019-11-08
Completion
2019-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275350 on ClinicalTrials.gov